【論文・学会活動～国際学会・研究会発表～】熊本大学病院　乳腺・内分泌外科

論文・学会発表

国際学会・研究会発表

065: Takashi Takeshita, Mai Tomiguchi, Aiko Sueta, Mutsuko Yamamoto-Ibusuki, Yutaka Yamamoto, Hirotaka Iwase. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer patients. AACR Annual Meeting 2018, poster, 2018/4/16, Chicago, IL

064: Yutaka Yamamoto. Treatment strategy for HER2-positive metastatic breast cancer. 3rd World Congress on Controversies in Breast Cancer, Morning Seminar, 2017/10/28, Tokyo
063: Mutsuko Yamamato-Ibusuki, Yutaka Yamamoto, Yoshitaka Fujuki, Aiko Sueta, Takashi Takeshita, Mai Tomiguchi, Lisa Goto, Hirotaka Iwase. “BRCAness”; a potential predictor needing the additional therapeutics. 15th St. Gallen International Breast Cancer Conference Primary Therapy of Early Breast Cancer. poster, 2017/3/17, Vienna, Austria

062: Mutsuko Yamamoto‐Ibusuki. “BRCAness”; a potential predictor needing the additional therapeutics. 15th St. Gallen International Breast Cancer Conference. poster, 2017/3/17, Vienna, Austria
061: Fujiki Y, Yamamoto Y, Yamamoto-Ibusuki M, Goto R, Tomiguchi M, Sueta A, Takeshita T and Iwase H. Development of a predictive model by gene expression profiles for pathological CR after neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. The 39th San Antonio Breast Cancer Symposiumu, poster, 2016/12/10, San Antonio, TX
060: Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, Goto-Yamaguchi L, Fujiki Y, Sueta A, Takeshita T and Iwase H. A comprehensive analysis of GNAS DNA copy number, levels of mRNA and protein expression in primary breast cancer. The 39th San Antonio Breast Cancer Symposiumu, poster, 2016/12/10, San Antonio, TX
059: Sueta A, Yamamoto Y, Tomiguchi M, Takeshita T, Ibusuki M and Iwase H. Differential expression of exosomal miRNAs between breast cancer patients with recurrence and no-recurrence. The 39th San Antonio Breast Cancer Symposiumu, poster, 2016/12/7, San Antonio, TX
058: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Sueta A, Tomiguchi M and Iwase H. Clinical significance of sequential measurements of ESR1 mutations in plasma cell-free DNA in estrogen receptor positive recurrent metastatic breast cancer patients. The 39th San Antonio Breast Cancer Symposiumu, poster, 2016/12/7, San Antonio, TX
057: Hirataka Iwase. The Current Status of Breast Surgery in japan. 3rd ‘Heart to Breast’ Forum, 2016/11/5, Shanghai
056: Yutaka Yamamoto. Treatment strategy for postmenopausal women with ER-positive/HER2-negative metastatic breast cancer. 14th Asia Breast Disease Association Meeting & Symposium, Oral presentation, 2016/9/3, Fukuoka
055: Hirotaka Iwase. Clinical significance of sequential measurement of ESR1 mutations in plasma cell-free DNA in metastatic breast cancer. 7th Seoul Breast Cancer Symposium 2016, Genomics, 2016/9/3, Seoul
054: Hirotaka Iwase. Treatment strategy for metastatic breast cancer withHER2-negative tumor. The 9th CCH International Breast Cancer Conference, Invited lecture, 2016/7/2, Taiwan
053: Yutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, Masahiro Kashiwaba, Naruto Taira, Masato Takahashi, Hiroshi Tada, Koichiro Tsugawa, Tatsuya Toyama,Naoki Niikura, Fumikata Hara, Tomomi Fujisawa, Tetsuhiro Yoshinami, Shigehira Saji, Toshimi Takano, Norikazu Masuda, Satoshi Morita, Masakazu Toi, Shinji Ohno. A randomized, open-label phase III trial of pertuzumabretreatment in HER2-positive locally advanced/metastatic breast cancer patients who had previously been treated with pertuzumab, trastuzumab, and chemotherapy：JBCRG-M05(PRECIOUS) trial. 2016 ASCO Annual Meeting, poster, 2016/6/1, Chicago,IL
052: Naoto Kondo, Yutaka Yamamoto, Hiroyasu Yamashiro, Masahiro Kashiwaba, Rikiya Nakamura, Masato Takahashi, Uhi Toh, Koichiro Tsugawa, Kazutaka Narui, Kentaro Tamaki, Tetsuhiro Yoshinami, Shoichiro Ohtani, Yuichiro Kai, Toshimi Takano, Yasuhiro Yanagita, Satoshi Morita, Masakazu Toi, Shinji Ohno. Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (JBCRG-C05: B-SHARE)：Interim safety analysis. 10th European Breast Cancer Conference, Poster, 2016/3/1, Amsterdam

051: Aiko Sueta, Yutaka Yamamoto, Takashi Takeshita, Mutsuko Yamamoto-Ibusuki, Hirotaka Iwase. High activation of PI3K pathway defined by PIK3CA mutation, PTEN, and INPP4B expression are associated with trastuzumab efficacy in HER2-positive breast cancer. The 38th San Antonio Breast Cancer Symposiumu, poster, 2015/12/12, San Antonio, TX
050: Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Toko Inao, Aiko Sueta, Saori Fujiwara, and Hirotaka Iwase. Clinical significance of ESR1 mutations using droplet digital polymerase chain reaction assay in 325 breast cancer samples. The 38th San Antonio Breast Cancer Symposiumu, poster, 2015/12/12, San Antonio, TX
049: Mai Tomiguchi, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Yoshitaka Fujiki, Lisa Goto-Yamaguchi, Saori Fujiwara, Aiko Sueta, Takashi Takeshita, Touko Inao, Hirotaka Iwase. FGFR-1 protein expression is associated with prognosis in primary breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression. The 35th San Antonio Breast Cancer Symposium, poster, 2015/12/12, San Antonio, TX
048: Saori Fujiwara, Noriko Saito, Saori Tomita, Mohamed Osama Abdalla, Hirotaka Iwase, Mitsuyoshi Nakao. Non-coding RNAs derived from near the ESR1 gene acts as a transcriptional regulator during estrogen deprivation adaptation of ER positive breast cancer cells. The 38th San Antonio Breast Cancer Symposiumu, poster, 2015/12/12, San Antonio, TX
047: Hirotaka Iwase, Takeshi Takeshita, Mutsuko Yamamoto-Ibusuki, Touko Inao, Aiko Sueta, Saori Fujiwara, Yutaka Yamamoto. ESR1 gene alterations in the metastatic breast cancer with resistance to aromatase inhibitor. Advances in Breast Cancer Research, poster, 2015/10/10, Bellevue, Washington
046: Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Toko Inao, Aiko Sueta, Saori Fujiwara, and Hirotaka Iwase. Clinical significance of ESR1 mutations by cell-free DNA in recurrent/ metastatic breast cancer. Advances in Breast Cancer Research, poster, 2015/10/10, Bellevue, Washington
045: Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Osako, Yasuo Toyozumi, Nobuyuki, Arima and Reiki Nishimura. Clinical and prognostic significance of menopausal status in triple negative breast cancer. 14th Breast Cancer Conference. Poster, 2015/3/20, Vienna, Austria

044: Hirotaka Iwase, Yoko Omoto, Takeshi Takeshita, Mutsuko Yamamoto-Ibusuki, Mitsuhiro Hayashi, Aiko Sueta, Saori Fujiwara, Yutaka Yamamoto. Ethinylestradiol treatment downregurates ER and upregurates PgR; Immunohistochemical analysis in postmenopausal breast cancer tissues after prior long-term estrogen-deprivation therapy. The 37th San Antonio Breast Cancer Symposium, poster, 2014/12/23, San Antonio, TX
043: Aiko Sueta, Yutaka Yamamoto, Mitsuhiro Hayashi, Takashi Takeshita, Mutsuko Ibusuki, Hirotaka Iwase. A role of MACC1 expression and its regulation of the HGF/c-Met pathway in breast cancer. The 37th San Antonio Breast Cancer Symposium, poster, 2014/12/23, San Antonio, TX
042: Saori Fujiwara, Noriko Saito, Saori Tomita, Mohamed Osama Abdalla, Hirotaka Iwase, Mitsuyoshi Nakao. Non-coding RNAs from ESR1 chromatin domain are involved in breast cancer adaptation to estrogen deprivation. 2014 Cold Spring Harbor Asia Conference RNA biology, poster, 2014/11/11, China
041: Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Osako, Yasuo Toyozumi, Nobuyuki, Arima and Reiki Nishimura. Prognosis according to year of recurrence and subtypein recurrent breast cancer. 18th SIS world congress on Breast Healthcare. Poster, 2014/10/8, Orlando, FL, USA
040: Toshimari Yamashita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Toko Inao, Mitsuhiro Hayashi, Aiko Sueta, Takashi Takeshita, K Kuroi, Hirotaka Iwase. Subsequent endocrine therapy after resistance to ethinylestradiol treatment for the late-stage metastatic breast cancer: A retrospective cohort study. ASCO BC, poster, 2014/9/25, San FranciscoCA
039: Hirotaka Iwase, Takashi Takeshita, Yoko Omoto, Mutsuko Ibusuki, Yutaka Yamamoto. Androgen receptor (AR) and phospho-AR protein levels in invasive breast cancers and survival outcomes: Indication of a new prognostic marker. ASCO BC, poster, 2014/9/4-6, San FranciscoCA
038: Mitsuhiro Hayashi, Yutaka Yamamoto, Aiko Sueta, Mai Tomiguchi, Saori Fujiwara, Satoko Yamamoto,Toko Inao, Mutsuko Yamamoto-Ibusuko, Hirotaka Iwase. Correlation between clinical tumor stiffness by elastography and response to neoadjuvant chemotherapy in patients with breast cancer. 50th Annual Meeting of the American Society of Clinical Oncology. poster, 2014/6, Chicago
037: Masahiro Nakano, Reiki Nishimura, Tomohumi Ohsako, Yasuyuki Nishiyama, Rumiko Tashima, Mamiko Fujisue, Yasuo Toyozumi, Nobuyuki Arima. Is the prognosis of recurrent breast cancer improving? 3rd International Breast Cancer Symposium, Oral, 2014/4/25, Jeju, Korea
036: Yutaka Yamamoto, Keisei Anan, Maki Tanaka, Shigeto Maeda, Hiroaki Ueo, Yoshiaki Sagara, Shinji Ohno, Teru Kawasoe, Hirotaka Iwase, Shoshu Mitsuyama, Kazuo Tamura. Phase II trial of triweekly nab-paclitaxel followed by 5-Fulorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients with operable breast cancer: KBC-SG 1103 trial. The 14th St. Gallen Breast Cancer Conference. poster, 2014/3/18, Vienna, Austria

035: Hayashi M, Shinriki S, Jono H, Nakamura T, Guo J, Yamamoto Y, Iwase H, Ando Y. Reduced expression of CYLD is an independent prognostic factor in breast cancer and confers treatment resistance and migratory activity in vitro. American Association for Cancer Research Annual Meeting 2013 Poster 2013-04-09 Washington DC
034: Okumura Y, Nishimura R, Nakatsukasa K, Yoshida A, Masuda N, Tanabe M, Shien T, Arima N, Komoike Y, Taguchi T, Inaji H, Ishitobi M. Changes in the biological markers between primary tumor and ipsilateral breast tumor recurrence after breast conserving surgery: discordance and prognosis. 49th Annual Meeting of the American Society of Clinical Oncology Poster 2013-06-01 Chicago,Illinois
033: Sueta A, Ito H, Islam T, Hosono S, Watanabe M, Iwata H, Tajima K, Tanaka H, Matsuo K, Iwase H. Associations of body-mass-index and its change with breast cancer risk by molecular subtypes: A case-control study in Japanese women. American Association for Cancer Reseach, annual meeting 2013 Poster 2013-04-09 Washington, DC
032: Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami K, Inao T, Okumura Y, Omoto Y. Prospective observational trial of re-antiestrogen therapy after becoming resistant to ethinylestradiol treatment in hormone-dependent metastatic breast cancer. 2013 Breast Cancer Symposium, ASCO Poster 9/7/2013 San Francisco, USA
031: Iwase H. Neoadjuvant therapy for early breast cancer in HER2 type and Luminal type tumors　Global Breast Cancer Conference 2013　Symposium 3 10/10/2013 Seoul, Korea
030: Iwase H, Kondo N, Yamashita T, Nakamura S, Ikeda M, Kawasoe T, Horio A, Yamamoto-Ibusuki M, Iwata H, Yamamoto Y. Clinical benefit of 'ethinylestradiol' as a salvage endocrine therapy for the heavily pretreated-metastatic breast cancer 2nd Meetng of Advanced Breast Cancer Poster 11/7/2013 Lisbon, Portugal
029: Iwase H, Yamamoto Y, Yamamoto-Ibusuki M, Murakami K, Inao T, Okumura Y, Omoto Y. Subsequent endocrine therapy after becoming to resistance of 'estrogen therapy' is beneficial as a salvage treatment for the late stage metastatic breast cancer. the 2013 CTRC-AACR San Antonio Breast Cancer Symposium Poster 12/11/2013 San Antonio, USA
028: Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Kondo N, Yamashita H, Toyama T, Takashi C, Saji S, Yamamoto-Ibusuki M, Iwase H. Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior non-steroidal aromatase inhibitor treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR ex study). The 36th San Antonio Breast Cancer Symposium Poster 2013-12-11 San Antonio, TX
027: Inao T, Harashima N, Yamamoto Y, Harada M, Iwase H. Poly(I:C), an innate adjuvant receptor ligand, can induce the antitumor effects on human breast cancer cells. The 36th San Antonio Breast Cancer Symposium Poster 2013-12-13 San Antonio, TX

026: Hayashi M, Shinriki S, Nakamura T, Ibusuki M, Sueyoshi T, Ota T, Yamamoto Y, Iwase H, Ando Y. Reduced CYLD expression is an independent prognostic factor in breast cancer: A possible link with RANKL-RANK signaling. American Association for Cancer Research Annual Meeting 2012 Poster 2012-04-01 Chicago, IL
025: Yamamoto Y, Yamaguchi R, Fujiki Y, Ibusuki M, Murakami K, Iwase H. Serum estradiol levels in postmenopausal ER+/PR- breast cancer are lower than those in postmenopausal ER+/PR+. OOTR (Organisation for Oncology and Translational Research) the 8th Annual Conference Poster 2012-04-21 Kyoto, Japan
024: Iwase H, Yamamoto Y, Ishikawa T, Hozumi Y, Ikeda M, Iwata H, Yamashita H, Toyama T, Chishima T, Kimijima I, Yamamoto-Ibusuki M, Saji S. Phase II randomized trial of toremifene 120 mg compared with exemestane 25 mg after prior nonsteroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive breast cancer. 2012 Breast Cancer Symposium, ASCO Poster Discussion 9/15/2012 San Francisco, USA.
023: Iwase H, Yamamoto Y, Murakami K, Yamamoto-Ibusuki M, Nakano M, Tomita S, Omoto Y. Ethinylestradiol is beneficial for postmenopausal advanced breast cancer patients heavily pre-treated with endocrine agents. The 2012 CTRC-AACR San Antonio Breast Cancer Symposium Poster 12/7/2012 San Antonio, USA
022: Yamamoto Y, Goto H, Ibusuki M, Murakami K, Iwase H. Serum estradiol levels in postmenopausal ER+/PR- breast cancer are lower than those in postmenopausal ER+/PR+. The 35th San Antonio Breast Cancer Symposium Poster 2012-12-08 San Antonio, TX 2005
021: Iwase H. Expression of ERa/b, PgR and Cofactors in Breast Cancer Tissues with Reference to the Response to Endocrine Therapy. 5th meeting of Asian Breast Cancer Society. Oral 4/21/2005 Tokyo
020: Omoto Y, Imamov O, Warner M, Gustafsson JÅ. New insight of estrogen receptors in growth and development of neonatal mouse ventral prostate. 2005 Gordon Research Conference: Hormone Action in Development & Cancer. Poster 2005/7/10-15 Boston, USA
019: Ibusuki M, Yamamoto Y, Kai K, Kawasoe T, Okumura Y, Iwase H. Hypoxia-inducible factor 1α is closely involved in an aggressive phenotype of breast cancer. The 2nd Annual Conference of Organization for Oncology and Translational Research Poster 2005-11-11 Tokyo

018: Ibusuki M, Yamamoto Y, Peifen Fu, Yamamoto S, Fujiwara S, Hayashi M, Iwase H. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. AACR Advances in breast cancer research Poster 2011/10/12-15 San Francisco
017: Yamamoto Y, Ibusuki M, Murakami K, Iwase H. Aurora A is closely linked to an aggressive phenotype of breast cancer. The 34th San Antonio Breast Cancer Symposium Poster 2011-12-09 San Antonio, TX
016: Sueta A, Ito H, Iwata H, Hosono S, Watanabe M, Iwase H, Tajima K, Tanaka H, Matsuo K. A Genetic Predictor for Breast Cancer Risk in a Japanese Population. The 34th San Antonio Breast Cancer Symposium Poster 2011-12-09 San Antonio, TX

015: Hayashi M, Nishimura R, Osako T, Okumura Y, Arima N. Changes in biological marker after neoadjuvant chemotherapy in primary breast cancer with or without trastuzumab. 6th Annual Conference of Organization for Oncology and Translational Research Poster 2010-02-26 Kyoto, Japan
014: Yamamoto Y, Ibusuki M, Fujimori H, Ota K, Ueda M, Shiniriki S, Taketomi M, Sakuma S, Shinohara M, Ando Y, Iwase H. Clinical significance of elevated plasma midkine levels in patients with breast cancer. OOTR (Organisation for Oncology and Translational Research) the 6th Annual Conference Poster 2010-02-27 Kyoto, Japan
013: Yamamoto Y, Ibusuki M, Fujimori H, Ota K, Ando Y, Iwase H. Midkine in the plasma as a novel breast cancer marker. 2010 Annual Meeting of ASCO Poster 2010-06-05 Chicago, IL
012: Murakami K, Yamamoto Y, Ibusuki M, Tsuchiya M, Goto H, Tomiguchi M, Iwase H. Clinical uesfulness of the high sensitive measurement of serum estradiol for endocrine therapy in breast cancer. 9th Asian Clinical Oncology Society poster 2010-08-26 GIFU
011: Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y, Iwase H. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. The 6th International symposium on Hormonal Oncogenesis Poster 2010-09-14 Tokyo
010: Hayashi M, Okumura Y, Osako T, Toyozumi Y, Arima N, Nishimura R. Time to first tumor progression as a predictor of efficacy of treatment with trastuzumab beyond progression in HER2-positive metastatic breast cancer. The American Society of Clinical Oncology 2010 Breast Cancer Symposium Poster 2010-10-02 Suburban Washington DC

009: Hayashi M, Okumura Y, Osako T, Arima N, Nishimura R. Effect of trastuzumab on the reduction of hormone receptor expression by neoadjuvant chemotherapy in HER2-positive breast cancer. 45th Annual Meeting of the American Society of Clinical Oncology Poster 2009-06-01 Orland, FL

008: Iwase H. Current Status of Endocrine Therapy for Breast Cancer - Optimizing by Biological Markers. 13th Aichi Cancer Center International Symposium. Oral 2/16/2008 Nagoya, Japan
007: Iwase H, Yamamoto Y, Otake T, Masuda N, Yamashita H, Saji S, Kimishima I, Kasahara Y, Ishikawa T, Sawaki M. Clinical Usefulness of High-dose Toremifene for Patients Failed by Treatment with Aromatase Inhibitor. 6thEuropean Breast Cancer Conference. Poster 2008/4/16-19 Berlin, Germany
006: Iwase H, Yamamoto Y, Kawasoe T, Ibusuki M, Nakano M, Tomita S, Hayashi M, Sueta A, Fujiwara S. Sentinel lymph node mapping using SPECT-CT fusion imaging in patients with breast cancer and its clinical usefulness. 2nd International Oncoplastic Breast Surgery. Oral 9/19/2008 Daegu, Korea

005: Ibusuki M, Yamamoto Y, Kawasoe T, Kai K, Shiraishi S, Tomiguchi S, Iwase H. Potential advantage of studying preoperative sentinel node mapping with three dimensional images by a hybrid single photon emission CT (SPECT)/CT system for breast cancer. 2007 American Society of Clinical Oncology Annual meeting Poster 2007/6/1-5 Chicago
004: Iwase H, Yamamoto Y, Kawasoe T, Yamashita H, Toyama T. Clinical Significance of Survivin Expression in Ductal Carcinoma in situ with Microinvasion of the Breast.　6th meeting of Asian Breast Cancer Society. Oral 2007/9/20-22 HongKong, China.
003: Yamamoto Y, Ibusuki M, Kawasoe T, Nakano M, Hayashi M, Sueta A, Iwase H. Triple negative breast cancer with basal-like feature has poor prognosis compared to that without basal-like feature. OOTR (Organisation for Oncology and Translational Research) the 4th Annual Conference Poster 2007-11-10 Kyoto, Japan

002: Iwase H, Zhang Z, Yamashita H, Yamamoto Y, Kai K, Kawaguchi M, Miura Y. Clinical Usefulness of ATBF1-A Expression in Breast Cancer as a Prognostic and Predictive Marker. 5thEuropean Breast Cancer Conference poster 2006/3/21-25 Nice, France
001: Yamamoto Y, Ibusuki M, Kawasoe T, Okumura Y, Kai K, Iwase H. Hypoxia-inducible factor 1a is closely linked to an aggressive phenotype in breast cancer. The 5th EBCC Poster 2006-03-23 Nice, France

論文・学会発表

国際学会・研究会発表

2018年

2017年

2016年

2015年

2014年

2013年

2012

2011

2010

2009

2008

2007年

2006年